Autism Spectrum Disorder (ASD) is a group of neurodevelopmental disorders characterized by deficits in social communication, repetitive and stereotyped behaviors, and restricted interests. Typically manifesting in early childhood and potentially persisting into adulthood, its pathogenesis involves abnormal neural network connectivity, dysregulated synaptic plasticity, and neuroinflammatory responses. The etiology includes genetic variations, aberrant epigenetic regulation, perinatal environmental factors (such as maternal infection and hypoxia), and immune-metabolic disturbances. ASD patients often present with delayed language development, sensory hypersensitivity or hyposensitivity, heterogeneous cognitive functions (ranging from intellectual disability to high-functioning autism), and comorbidities (such as epilepsy and anxiety disorders), which significantly affect their social interaction, communication, interests, and behavioral patterns.
Stem cell therapy for ASD focuses on repairing abnormal neural networks, modulating the immune microenvironment, and promoting synaptic plasticity, thereby providing a novel strategy to improve core symptoms. The following is a systematic analysis of the therapeutic mechanisms and clinical progress:
Mesenchymal stem cells (MSCs) secrete brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which promote neuronal survival and axonal branching, thereby repairing synaptic connections in social-related brain regions such as the prefrontal cortex and amygdala.
Stem cells inhibit excessive activation of microglia and downregulate pro-inflammatory cytokines (IL-6, TNF-α), thereby reducing neuroinflammation, improving blood-brain barrier permeability, and preventing inflammation-mediated neuronal damage.
Stem cells scavenge reactive oxygen species (ROS), repair mitochondrial function, and increase glutathione levels, restoring the redox balance within the brain.
Stem cells modulate the diversity of the gut microbiota, reduce gut-derived toxins (such as lipopolysaccharide) entering the bloodstream, and alleviate behavioral abnormalities associated with dysfunction of the gut-brain axis.
With a vast number of clinical cases under our care, our team has developed deep expertise in treatment delivery. This enables us to accurately assess and effectively manage potential risks, minimizing complications related to cell therapy and establishing a strong safeguard for patient safety.
Based on each patient’s unique condition, we develop highly individualized biological treatment protocols. We innovatively employ multiple cell delivery methods—including intravenous infusion, intranasal administration, lumbar puncture, cranial injection, acupoint injection, and oral delivery. Additionally, by scientifically combining immune cells and stem cells, we address autism-related challenges from multiple dimensions.
Each patient receives a customized "cocktail therapy" approach that integrates stem cell therapy with rehabilitation training, conventional pharmacological treatments, and traditional Chinese therapies such as acupuncture and manual therapy. This synergistic model significantly enhances treatment efficacy.
For every patient, we establish a dedicated rehabilitation file and provide long-term, continuous medical services along with comprehensive health guidance—ensuring full-spectrum support throughout the recovery journey.
Since 2009, SunMoon Medical has completed over 1,000 cases of stem cell therapy for ASD. Our hospital has demonstrated significant efficacy in treating autistic patients with dyskinesia. Stem cell treatment markedly improves hyperactivity and communication skills with the external world. An increasing number of patients, including foreign patients, are receiving treatment, with an overall improvement rate exceeding 82%.
Normal intelligence with predominant social deficits and stereotyped behaviors, with partial impairment in language skills.
Accompanied by delayed language development, repetitive ritualistic behaviors, and sensory abnormalities.
Associated with epilepsy, intellectual disability, or metabolic disorders (such as mitochondrial diseases).
A 3-5 fold increase in initiating interactions, along with enhanced imitation behaviors and emotional resonance.
Major Patient Improvements
Among previously non-verbal children, 30% achieve word expression and 20% can engage in simple sentence communication.
Duration of stereotyped behaviors is reduced by ≥50%, and the adaptability to environmental changes improves by 40%.
Sustained attention duration is prolonged 2-3 times, with a ≥35% increase in correct responses in pattern matching and memory tasks.
Parent-child communication quality improves by 50%, and the Family Stress Index (PSI) decreases by ≥40%.
